Skip to main content

The Nasdaq and Amex biotech indices were down 2.2% and 2.6%, respectively.

The Wall Street Journal

reported late Wednesday that

Eli Lilly

(LLY) - Get Free Report




mystery bidder. Later Wednesday, ImClone Chairman Carl Icahn said in a release that the mystery suitor made a proposal not subject to financing or further due diligence. Negotiations are reportedly under way and the company has requested that ImClone not reveal the bidder's name until negotiations are complete.

ImClone shares were trading up 35 cents, or 0.5%, at $65.70. Eli Lilly shares were down 30 cents, or 0.7%, at $43.39.

Shares of

Bristol Myers Squibb

(BMY) - Get Free Report

, which last week announced a hostile tender for ImClone at $62 a share, were down 10 cents, or 0.5%, at $20.69.

In other big biotech merger news, Roche reaffirmed that it's committed to a deal with


( DNA). Investor skepticism about the financing of the proposed $89 a share buyout has recently depressed the share price. Shares were up 20 cents, or 0.2%, at $86.70 in recent trading Thursday.

In pharma news,


(MRK) - Get Free Report

said Thursday that it is discontinuing the late-stage clinical development program for taranabant for obesity and will not seek regulatory approval for the drug in that indication. The company said that available phase III data showed that both efficacy and adverse events were dose related, with greater efficacy and more adverse events in the higher doses.

Lazard analysts said it was no surprise as the safety and efficacy from taranabant's drug class, which includes Sanofi Aventis' Zimulti, for example, have disappointed. Merck's shares were off by 25 cents, or 0.8%, at $31.84.

Last, an analyst action for




Rodman & Renshaw

(RODM) - Get Free Report

raised its 15-month price target to a whopping $65 from $25, while maintaining a market perform, speculative risk rating. The analyst projects that sales of genetic material-based non-invasive prenatal diagnostics could exceed $1 billion in firm revenue by 2011, $2 billion by 2013 and $3 billion by 2016.

Sequenom shares were up 28 cents, or 1%, at $27.